4//SEC Filing
Ioannidou Sofia 4
Accession 0000899243-18-027478
CIK 0001664106other
Filed
Oct 24, 8:00 PM ET
Accepted
Oct 25, 6:25 PM ET
Size
9.5 KB
Accession
0000899243-18-027478
Insider Transaction Report
Form 4
Ioannidou Sofia
Director
Transactions
- Purchase
Common Stock
2018-10-23$10.00/sh+420,000$4,200,000→ 1,787,413 total(indirect: See Footnote) - Conversion
Series B Convertible Preferred Stock
2018-10-23−2,611,665→ 0 total(indirect: See Footnote)→ Common Stock (1,367,413 underlying) - Conversion
Common Stock
2018-10-23+1,367,413→ 1,367,413 total(indirect: See Footnote)
Footnotes (2)
- [F1]Upon closing of the Issuer's initial public offering, each share of Series B Convertible Preferred Stock automatically converted into 0.5235794 shares of Common Stock without payment or further consideration. There was no expiration date for the Series B Convertible Preferred Stock.
- [F2]The Reporting Person is a director of Andera Partners, the company managing BioDiscovery 5. BioDiscovery 5 is the direct beneficial owner of these securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of these securities in which the Reporting Person has no pecuniary interest.
Documents
Issuer
LogicBio Therapeutics, Inc.
CIK 0001664106
Entity typeother
Related Parties
1- filerCIK 0001752486
Filing Metadata
- Form type
- 4
- Filed
- Oct 24, 8:00 PM ET
- Accepted
- Oct 25, 6:25 PM ET
- Size
- 9.5 KB